Lepsi

Lepsi 100mg/ml oral solution contains Levetiracetam, an antiepileptic drug that modulates synaptic vesicle protein SV2A, inhibiting neurotransmitter release and stabilizing neuronal membranes to suppress seizure spread. It is rapidly absorbed with nearly complete bioavailability, independent of food, and primarily renally excreted, making it suitable for adjunctive therapy in partial-onset seizures with or without secondary generalization. Clinical evidence shows it reduces seizure frequency by 50% or more in 20-40% of patients, with a favorable profile for pediatric and adult use.

Key Benefits:

• Rapid onset and high bioavailability for consistent seizure control
• Liquid formulation ideal for pediatrics or swallowing difficulties
• Low drug interaction potential
• Does not induce hepatic enzymes
• Supports monotherapy or adjunctive use in refractory epilepsy

How to Use

• Administration: Take orally; shake well before measuring. Use provided syringe or measuring device for accurate dosing.
• Timing: With or without food; twice daily for most regimens.
• Dosage: Individualized by weight/renal function; adults typically 1000-3000mg/day (10-30ml of 100mg/ml solution). Pediatric: 20-60mg/kg/day divided BID. Adjust for CrCl <80ml/min.
• Consistency: Take at regular intervals; do not abruptly stop—taper gradually.
• Monitoring: Regular seizure logs; renal function assessments.

Expert Tips from CureCart Direct:

• Stay hydrated to support renal clearance and prevent dehydration.
• Use pill reminder apps or alarms for adherence; involve caregivers for children.
• Report mood/behavior changes immediately—monitor weekly initially.
• Avoid alcohol; it may potentiate CNS depression.
• For elderly/renal patients, start low and titrate slowly per CrCl calculations.

Missed Dose: Take as soon as remembered unless near next dose—skip and resume. Do not double. Consult for multiple misses.

Overdose: Symptoms include somnolence, agitation, respiratory depression—seek emergency care. Hemodialysis effective for removal.

Primary Uses

• Adjunctive treatment of partial-onset seizures with/without secondary generalization.
• Management of myoclonic seizures in juvenile myoclonic epilepsy.
• Therapy for primary generalized tonic-clonic seizures.

Indications

Indicated as adjunctive therapy for adults (≥16 years) and children (≥1 month) with partial-onset seizures, myoclonic seizures (≥12 years), or primary generalized tonic-clonic seizures (≥6 years). Oral solution preferred for infants/young children or precise dosing needs. Monotherapy possible in some partial seizures.

Side Effects

Common:

• Somnolence, dizziness, asthenia
• GI upset (anorexia, diarrhea)
• Accidental injury, infection

Less Common:

• Behavioral changes (irritability, aggression)
• Headache, vertigo
• Elevated liver enzymes

Serious/Rare:

• Suicidal ideation/behavior (monitor closely)
• Psychotic symptoms, pancytopenia
• Severe skin reactions (e.g., Stevens-Johnson syndrome)
• Paradoxical seizure worsening

Report prolonged symptoms or mood shifts promptly.

Warnings and Precautions

• Pregnancy: Use cautiously; limited data—enroll in pregnancy registry if applicable. Potential neural tube defect risk.
• Lactation: Contraindicated; detected in breast milk—consider alternatives.
• Driving: Avoid until seizure-free and effects known; impairs coordination.
• Alcohol: Avoid; increases sedation/seizure risk.
• Renal Impairment: Dose adjust by CrCl; contraindicated if anuria.
• Hepatic Impairment: Caution; no adjustment but monitor.
• Elderly: Start low due to renal decline; monitor for falls.
• Other: Screen for psychiatric history; watch for blood dyscrasias, fever.

Contraindications

Do not use in:

• Known hypersensitivity to Levetiracetam or excipients.
• Lactating females (without expressed consent).
• Severe renal failure on dialysis (adjust dosing).

FAQs

What are the uses? Adjunctive treatment for epilepsy types including partial, myoclonic, and tonic-clonic seizures.

Storage? Room temperature (18-25°C), away from light/moisture/children. Do not flush; pharmacist disposal.

Response time? Rapid absorption; peak 1 hour post-dose. Seizure reduction in 20-40% patients by 50%+.

Makes me sleepy? Yes; avoid driving/machinery until tolerated.

Suicidal risk? Increased with anti-epileptics; monitor for depression/mood changes.

Overdose symptoms? Drowsiness, agitation, respiratory issues, fainting—emergency care.

Avoid while taking? Alcohol; report bleeding, rashes, worsening seizures.

Related Tests: Renal function (CrCl), CBC, EEG, seizure frequency logs.

Doctor Review

Dr. Tariq Mehmood, MBBS, FCPS – Consultant Neurologist “Levetiracetam 100mg/ml oral solution offers SV2A modulation for hypersynchronization inhibition, achieving rapid absorption with Tmax ~1 hour and 96% bioavailability, ideal for pediatric titration. Pharmacokinetics show linear clearance (0.96ml/min/kg) predominantly renal, necessitating CrCl-based adjustments to prevent accumulation in impaired function. Clinical efficacy in adjunctive partial seizures reaches 50% responder rates in RCTs, with behavioral AEs (irritability 13%) often dose-related and transient. Unlike enzyme inducers, minimal interactions support polytherapy, though psychiatric monitoring remains paramount given 0.2% suicide risk elevation in meta-analyses. Liquid form facilitates precise dosing in infants ≥1 month, underscoring its versatility in refractory epilepsy management.”

Disclaimer: This information is for educational purposes only and not a substitute for professional medical advice. Always consult a qualified physician before use. CureCart Direct ensures accurate details but cannot cover all interactions or precautions. Prices and availability subject to change.